Back to Journals » Virus Adaptation and Treatment » Volume 3

Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection

Authors Rampling T, Nelson M

Published 25 March 2011 Volume 2011:3 Pages 25—34

DOI https://doi.org/10.2147/VAAT.S15680

Review by Single-blind

Peer reviewer comments 3

Thomas Rampling, Mark Nelson
Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Abstract: The protease inhibitor atazanavir (ATV) now forms an integral component of many combination antiretroviral regimens. It has been shown to have a favorable side effect profile, and it does not negatively affect plasma lipids as some other protease inhibitors can. ATV also has a long half-life, which allows for a once-daily dosing schedule. Coadministration of ATV with low-dose ritonavir (RTV) potentiates the effect of ATV ("RTV boosting"), allowing for lower doses of ATV than those prescribed without RTV. ATV boosted with RTV (ATV/r) has shown noninferiority to RTV-boosted lopinavir (LPV/r), and it has been shown to be effective as a simplification strategy in switch studies. ATV/r-based regimens have also shown promise as a rescue strategy for patients failing other regimens. Several important adverse events and drug interactions have been identified, and care must be taken when administering ATV with other medications. The most commonly reported adverse effect is unconjugated hyperbilirubinemia, which occurs as a result of the metabolic pathway by which it is excreted. Resistance to ATV has been described in both treatment-experienced and treatment-naïve patients.

Keywords: atazanavir, HIV, protease inhibitors, drug resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Developing a discrete choice experiment in Malawi: eliciting preferences for breast cancer early detection services

Kohler RE, Lee CN, Gopal S, Reeve BB, Weiner BJ, Wheeler SB

Patient Preference and Adherence 2015, 9:1459-1472

Published Date: 14 October 2015

Predictors of overall satisfaction of cancer patients undergoing radiation therapy

Becker-Schiebe M, Pinkert U, Ahmad T, Schäfer C, Hoffmann W, Franz H

Patient Preference and Adherence 2015, 9:1381-1388

Published Date: 29 September 2015

Mechanisms underlying probucol-induced hERG-channel deficiency

Shi YQ, Yan CC, Zhang X, Yan M, Liu LR, Geng HZ, Lv L, Li BX

Drug Design, Development and Therapy 2015, 9:3695-3704

Published Date: 20 July 2015

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010